Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04217018

MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

MR Based Prediction of Molecular Biomarkers or Subgroups in Primary Glioma Using Deep Learning or Machine Learning

Status
Recruiting
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
The First Affiliated Hospital of Zhengzhou University · Academic / Other
Sex
All
Age
1 Year – 95 Years
Healthy volunteers
Accepted

Summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.

Detailed description

Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging. With the development of artificial intelligence, much more potential lies in the preoperative conventional/advanced MR imaging (T1 weighted imaging, T2 weighted imaging, FLAIR, contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, and perfusion imaging) could be excavated to aid prediction of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed molecular pathology, radiological data and with sufficient sample size for deep learning (\>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPrediction of molecular pathologyPrediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI

Timeline

Start date
2017-01-01
Primary completion
2027-01-01
Completion
2027-06-01
First posted
2020-01-03
Last updated
2021-02-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04217018. Inclusion in this directory is not an endorsement.